Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Co-careldopa 25mg/100mg tablets
0409010N0AAABAB
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 66,162 |
|
Co-careldopa 12.5mg/50mg tablets
0409010N0AAADAD
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 52,230 |
|
Sinemet Plus 25mg/100mg tablets
0409010N0BBACAB
|
Sinemet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 38,820 |
|
Half Sinemet CR 25mg/100mg tablets
0409010N0BBAFAG
|
Sinemet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 36,654 |
|
Sinemet 12.5mg/50mg tablets
0409010N0BBAGAD
|
Sinemet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 33,501 |
|
Co-careldopa 25mg/100mg modified-release tablets
0409010N0AAAGAG
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 32,976 |
|
Sinemet CR 50mg/200mg tablets
0409010N0BBAEAE
|
Sinemet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 14,844 |
|
Co-careldopa 50mg/200mg modified-release tablets
0409010N0AAAEAE
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 9,702 |
|
Sinemet 25mg/250mg tablets
0409010N0BBABAC
|
Sinemet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 2,109 |
|
Co-careldopa 25mg/250mg tablets
0409010N0AAACAC
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 1,686 |
|
Co-careldopa 10mg/100mg tablets
0409010N0AAAAAA
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 1,031 |
|
Sinemet 10mg/100mg tablets
0409010N0BBAAAA
|
Sinemet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 673 |
|
Caramet 25mg/100mg CR tablets
0409010N0BEAAAG
|
Caramet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 541 |
|
Co-careldopa 25mg/100mg/5ml oral suspension
0409010N0AAAUAU
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 122 |
|
Co-careldopa 12.5mg/50mg/5ml oral suspension
0409010N0AAAVAV
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 87 |
|
Lecado 100mg/25mg modified-release tablets
0409010N0BFAAAG
|
Lecado | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 27 |
|
Co-careldopa 25mg/100mg/5ml oral solution
0409010N0AAAKAK
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 20 |
|
Lecado 200mg/50mg modified-release tablets
0409010N0BFABAE
|
Lecado | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 14 |
|
Co-careldopa 6.25mg/25mg/5ml oral suspension
0409010N0AAAPAP
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 13 |
|
Co-careldopa 3.125mg/12.5mg/5ml oral suspension
0409010N0AAAWAW
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 5 |
|
Co-careldopa 50mg/200mg/5ml oral suspension
0409010N0AAANAN
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 5 |
|
Caramet 50mg/200mg CR tablets
0409010N0BEABAE
|
Caramet | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 4 |
|
Levodopa 20mg/ml/Carbidopa monohydrate 5mg/ml intestinal gel
0409010N0AAARAR
|
Co-careldopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 2 |
|
Duodopa intestinal gel 100ml cassette
0409010N0BDAAAR
|
Duodopa | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | 1 |
|
Apodespan PR 50mg/200mg tablets
0409010N0BGAAAE
|
Apodespan | Co-careldopa (Carbidopa/levodopa) | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.